Rigvir holding successfully attracted investments of EUR 500,000
The investment will be used in accordance with the Rigvir science program to strengthen the product's scientific capacity.
Read More
Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir
Adrenal gland melanoma is an extremely rare diagnosis with less than 20 cases reported.
Read More
Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines
The results suggest cytolytic activity of oncolytic ECHO-7 virus strain Rigvir in MP41, 92-1 and Mel-202 cell lines.
Read More
Attention, counterfeit!
A counterfeit of medicine Rigvir has been detected, which is being distributed in Russia, Ukraine, Kazakhstan and possibly other countries. Counterfeit medicines are easily identifiable visually.
Read More
A Case Report published: ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma
This report describes a stage I uveal melanoma patient treated with oncolytic virus Rigvir as an adjuvant therapy.
Read More
A Case Report published: Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir
This report describes a stage III glottic cancer patient treated with Rigvir therapy.
Read More
Combining checkpoint inhibitors with oncolytic virotherapy can be a gamechanger
Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient
Read More
Rigvir improves control and circulation of medicines
Drug testing methodes could be reorganised soon.
Read More
Rigvir Group is looking for partners globally
To finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.
For Investors
A Case Report published: Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus
Metastatic renal cell carcinoma can be resistant to cytotoxic chemotherapy. This report is of a case of stage IV chromophobe renal cell carcinoma that responded well to Rigvir® treatment.
Full Article
Rigvir Group has sold International Virotherapy Center
This is the part of the strategy to focus all the resources exclusively on the biotech format.
Read More
The Advent of Oncolytic Virotherapy in Oncology: The Rigvir® Story
Numerous viruses have been tested in clinical trials and three are approved. Our virus was the first.
Full Publication
Rigvir follow-up titre analyses completed
The Rigvir Group has conducted a series of drug tests and found several batches that do not conform with the specification. Sales of the specific batches have been halted in a timely manner. There has been no risk to the health and safety of patients, but a minor and short-term potential effect on therapeutic efficacy for a small number of vials has been identified.
Read More
Pioneers of Oncolytic Virotherapy with Biotechnological Focus
We are committed to prove, that the cancer treatment can be safe, effective and harmless.
Our Company
We are Excited About the Future and Proud of Our Past
In the 1960s with the efforts of professor Aina Muceniece the focus points in the perception of cancer started to shift.
Our HistoryWatch Video
We Believe in the Good Virus
We invest in biomanufacturing and we focus on growing our portfolio of virotherapy medicines that meet the real needs of patients.
Products
From Virotherapy Focus to Vision of Life Science
Innovations in biotechnological cancer treatments are the key concepts for improving the health quality of global population.
Focus Areas